OmniAb (OABI) Insider Jennifer Cochran Buys 20,000 Shares

Insider Buying and Selling at OmniAb, Inc.

On June 17, 2026, Jennifer Cochran, an insider at OmniAb, Inc. (OABI), bought 20,000 shares of the company. The shares were purchased on a day when the stock was trading at $2.34. This acquisition comes as part of a broader trend of insider trading at OmniAb, reflecting a mix of buying and selling among its executives.

Other Insider Trades on the Same Day

On the same day, several other insiders also made trades in OmniAb. Steven Love sold 20,000 shares, while he also acquired 40,000 shares. Steven Crouse sold 20,000 shares but also bought 20,000 shares. Philip Gotwals and John Higgins each sold 20,000 shares. This activity underscores a complex pattern of trading among the company's executives, with both selling and buying occurring simultaneously.

Stock Performance and Market Context

OmniAb's stock is currently trading at $2.34, which is significantly below its 52-week high of $5.43. The stock has seen volatility, with a 52-week low of $1.30. Given the recent insider purchases, some investors may see this as a potential opportunity, especially with analysts projecting a mean price target of $8.4.

Analysts Set New Price Targets

On October 7, 2026, Leerink Partners maintained an "Outperform" rating on OmniAb with a price target of $12.00, up from a prior target of $10.00. StoneX also maintained a "Buy" rating with a new price target of $6.00, increased from $4.00. HC Wainwright & Co. reiterated a "Buy" rating with a target of $11.00. The overall analyst sentiment appears positive, with five analysts providing opinions that support a bullish outlook for the stock.

What OmniAb, Inc. Does

OmniAb, Inc. is a biotechnology company that licenses technology to aid in drug discovery for pharmaceutical and biotech firms, as well as academic institutions. Its platform is designed to create and screen diverse antibody repertoires, which can be crucial for developing new therapeutics. This insider buying could indicate confidence in the company's future prospects as it moves forward in the biotechnology space.

What's Ahead for OmniAb, Inc.

Investors will be watching for OmniAb's next earnings report scheduled for November 4, 2026. The recent trades by insiders, particularly the purchases, suggest that some executives are optimistic about the company's direction. The Form 4 filings reflect these transactions but may not represent the current positions of the insiders.